Sonoma Biotherapeutics Funding & Investors
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
sonomabio.comTotal Amount Raised: $365,000,000
Sonoma Biotherapeutics Funding Rounds
Corporate Round
$30,000,000
Corporate Round Investors
Regeneron PharmaceuticalsSeries B
$265,000,000
Series B Investors
Lilly Asia VenturesAvidity PartnersJDRF T1D FundNS InvestmentArrowMark PartnersArch Venture PartnersLifeforce CapitalFidelity Management and Research CompanyAlexandria Venture InvestmentsAlly Bridge GroupOsage University PartnersOctagon Capital Advisors8VCVertex Ventures HCFrazier ManagementHenderson Global InvestorsMirae AssetGVDeep Track CapitalCasdin CapitalSeries A
$30,000,000
Series A Investors
Lilly Asia VenturesJDRF T1D FundOctagon Capital Advisors8VCArch Venture PartnersLifeforce CapitalLyell ImmunopharmaAlexandria Venture InvestmentsSeries A
$40,000,000
Series A Investors
8VCArch Venture PartnersMilky Way VenturesLyell Immunopharma
Funding info provided by Diffbot.